Dr. Shen is currently Vice President, Strategic Innovation Leaders at Mass General Brigham, an affiliate of Harvard Medical School. She received a BS through Rensselaer’s accelerated biomedical program, an MD from Albany Medical College in New York, and MBA from NYU Stern School of Business.
Dr. Shen provides expertise in translational medicine, clinical development, and regulatory affairs for novel therapies being developed at Mass General Brigham, with a focus on the gene & cell therapy portfolio. She has served as Chief Medical Officer (CMO) at multiple venture-backed biotech startups including Walking Fish, Arcellx, NKarta, Arvinas, and acting CMO of Tizona. Dr. Shen has led oncology and rare disease programs in a variety of pharmaceutical settings for 17+ years through all stages of drug development including IND filings, first-in-human trials, registrational trials, and NDA/BLA filings. While working in oncology clinical development at Novartis, Dr. Shen was extensively involved with in-licensing University of Pennsylvania’s CAR-T technology. She assembled and led the clinical team responsible for designing and launching the industry’s first multi-site, registration CAR-T trial, which resulted in the approval of Kymriah® (CTL019, CART-19). Prior to that, Dr. Shen made key contributions to the development of several oncology drugs within Novartis, Exelixis, and Johnson & Johnson.
